XNCR — Xencor Inc
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1326732 ·
Last close
$20.21
Market Cap
$1.50B
52W High
$21.76
52W Low
$10.38
ADV30
1,125,703
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 4,516,000 | — | -77,862,000 | -128,916,000 | 736,846,000 | 14,170,000 | 221,213,000 |
| Dec 2025 | 28,237,000 | — | -53,628,000 | -6,653,000 | 875,495,000 | 54,073,000 | 239,908,000 |
| Sep 2025 | 20,999,000 | — | -47,519,000 | -6,027,000 | 868,811,000 | 28,291,000 | 243,495,000 |
| Jun 2025 | 43,608,000 | — | -33,172,000 | -30,825,000 | 879,424,000 | 44,442,000 | 259,073,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-135,117,000
Investing CF
$139,985,000
Financing CF
$8,232,000
CapEx
$-3,150,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.24
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-795,959,000
Inventory
—
Receivables
$29,299,000
ST Investments
$493,660,000
EBIT TTM
$-57,706,000
Pretax Income TTM
$-89,633,000
Interest Exp TTM
$31,927,000
Analysts
12
Yahoo Snapshot (yfinance, live)
Total Revenue
$97,360,000
EBITDA
$-201,795,008
Free Cash Flow
$-76,885,376
Enterprise Value
$1,228,615,680
Total Cash
$444,950,016
Total Debt
$175,164,000
Shares Out
74,141,596
Trailing EPS
$-2.29
Book Value
$6.96
ROE
-29.8%
ROA
-16.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 125,576,000 | -177,502,000 | -91,923,000 | 875,495,000 | 239,908,000 | — | -135,117,000 |
| Dec 2024 | 110,493,000 | -178,408,000 | -232,618,000 | 951,945,000 | 277,919,000 | — | -202,188,000 |
| Dec 2023 | 174,615,000 | -132,362,000 | -133,133,000 | 965,135,000 | 303,048,000 | — | -77,926,000 |
| Dec 2022 | 164,579,000 | -82,473,000 | -55,181,000 | 846,266,000 | 118,770,000 | — | 24,485,000 |
TTM Snapshot
Revenues TTM
$104,259,000
NetIncome TTM
$-103,316,000
OpCashFlow TTM
$0
Assets (Latest)
$951,945,000
Forward EPS
$-3.55
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CMPS | COMPASS Pathways plc | $1.53B | $11.35 | — |
| TRAX | First Tracks Biotherapeutics, Inc. | $1.54B | $44.04 | — |
| INVA | Innoviva, Inc. | $1.55B | $20.97 | — |
| SEPN | Septerna, Inc. | $1.55B | $34.45 | — |
| HROW | HARROW, INC. | $1.45B | $38.77 | — |
News headlines (Yahoo Finance, 1h cache)
Sector Update: Healthcare Stocks Decline Late Afternoon
2026-07-30 19:46 · Yahoo
Xencor to Receive $105 Million From Alexion to Resolve Ultomiris® U.S. Royalty Matter
2026-07-29 20:01 · Yahoo
Xencor (XNCR) Soars 16.9%: Is Further Upside Left in the Stock?
2026-07-20 11:26 · Yahoo
Sector Update: Healthcare Stocks Mixed Late Afternoon
2026-07-17 19:44 · Yahoo
Xencor Announces Proffered Paper Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
2026-07-17 13:11 · Yahoo
VERAXA Biotech Stock in Focus as Lead Cancer Program Reaches Development Milestone
2026-07-02 22:40 · Yahoo
Xencor (XNCR) Stock Draws Fresh Price Target Split As Pipeline Progress Meets Caution
2026-06-14 05:11 · Yahoo
Bi/Multispecific Drugs in Oncology Analytical Tool Featuring Top Developers - Amgen, Hoffmann-La Roche, J&J, Xencor, Biocytogen - Unlocking New Precision, Immune Activation, and Therapeutic Potential
2026-05-12 09:22 · Yahoo
These Analysts Think Xencor, Inc.'s (NASDAQ:XNCR) Sales Are Under Threat
2026-05-08 11:11 · Yahoo
Xencor (XNCR) Reports Q1 Loss, Lags Revenue Estimates
2026-05-06 21:10 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.